A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

The Gene Editing Therapeutics market, driven by advancements in CRISPR technology and precision medicine, presents opportunities in oncology, rare genetic disorders, and chronic diseases. Investment ...

People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...

Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...

An extremely precise genome editing technique called base editing has been used for the first time by Cambridge scientists to ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.